ArticleOxidative medicine and cellular longevity2016
Vasorelaxant Effect of a New Hydrogen Sulfide-Nitric Oxide Conjugated Donor in Isolated Rat Aortic Rings through cGMP Pathway.
Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease.Pharmaceutics · 2022Review
- Hydrogen Sulfide-Induced Vasodilation: The Involvement of Vascular Potassium Channels.Frontiers in pharmacology · 2022Review
- HBiomolecules · 2021Review
- Phosphorylation of Akt at Thr308 regulates p-eNOS Ser1177 during physiological conditions.FEBS open bio · 2021Article
- Trends in HAntioxidants (Basel, Switzerland) · 2021Review
- Highly efficient HChemical science · 2020Article
- Advances in the Protective Mechanism of NO, HFrontiers in cardiovascular medicine · 2020Review
- An Appraisal of Developments in Allium Sulfur Chemistry: Expanding the Pharmacopeia of Garlic.Molecules (Basel, Switzerland) · 2019Review
- Effects of a novel hydrogen sulfide prodrug in a porcine model of acute limb ischemia.Journal of vascular surgery · 2019Article
- Role of Nitric Oxide in the Cardiovascular and Renal Systems.International journal of molecular sciences · 2018Review
- Novel HRedox biology · 2018Article
- Regulation of vascular tone homeostasis by NO and HBiochemical pharmacology · 2018Review
- Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation.Biochemical pharmacology · 2018Article
- An Update on Hydrogen Sulfide and Nitric Oxide Interactions in the Cardiovascular System.Oxidative medicine and cellular longevity · 2018Review
- International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of HPharmacological reviews · 2017Review
- Role of thiosulfate in hydrogen sulfide-dependent redox signaling in endothelial cells.American journal of physiology. Heart and circulatory physiology · 2017Article
- Therapeutic Role of Functional Components in Alliums for Preventive Chronic Disease in Human Being.Evidence-based complementary and alternative medicine : eCAM · 2017Review
- Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications.American journal of physiology. Cell physiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelium-dependent vasorelaxant injury leads to a lot of cardiovascular diseases. Both hydrogen sulfide (H2S) and nitric oxide (NO) are gasotransmitters, which play a critical role in regulating vascular tone. However, the interaction between H2S and NO in vasorelaxation is still unclear. ZYZ-803 was a novel H2S and NO conjugated donor developed by H2S-releasing moiety (S-propyl-L-cysteine (SPRC)) and NO-releasing moiety (furoxan). ZYZ-803 could time- and dose-dependently relax the sustained contraction induced by PE in rat aortic rings, with potencies of 1.5- to 100-fold greater than that of furoxan and SPRC. Inhibition of the generations of H2S and NO with respective inhibitors abolished the vasorelaxant effect of ZYZ-803. ZYZ-803 increased cGMP level and the activity of vasodilator stimulated phosphoprotein (VASP) in aortic rings, and those effects could be suppressed by the inhibitory generation of H2S and NO. Both the inhibitor of protein kinase G (KT5823) and the inhibitor of KATP channel (glibenclamide) suppressed the vasorelaxant effect of ZYZ-803. Our results demonstrated that H2S and NO generation from ZYZ-803 cooperatively regulated vascular tone through cGMP pathway, which indicated that ZYZ-803 had therapeutic potential in cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.